Intravacc Secures French Tax Credit to Fuel Vaccine Innovation

BILTHOVEN, The Netherlands – May 27, 2026 – In a strategic move set to reshape R&D partnerships in the European life sciences sector, Dutch contract development and manufacturing organization (CDMO) Intravacc announced it has received approval for France's prestigious Research Tax Credit, or Crédit d’Impôt Recherche (CIR). The approval, granted by the French Ministry of Higher Education, Research and Space, designates Intravacc as a qualified private research organization for the years 2025, 2026, and 2027.

This certification allows French pharmaceutical and biotech companies to claim significant tax credits on outsourced R&D activities performed by Intravacc. The development provides a powerful financial incentive for French innovators to access Intravacc's specialized expertise in vaccine and biologics development, potentially accelerating the journey of new medical solutions from the laboratory to the clinic.

Understanding France's Premier R&D Incentive

The Crédit d’Impôt Recherche is the cornerstone of France's strategy to stimulate private sector innovation and is widely regarded as one of the most generous R&D tax incentives in Europe. With an annual government expenditure that recently topped €7.6 billion, the CIR is a critical financial lever for the nearly 20,000 companies that utilize it each year.

The mechanism is straightforward but impactful: it provides companies with a tax credit equivalent to 30% of their eligible R&D expenses up to €100 million, and 5% for expenses beyond that threshold. For small and medium-sized enterprises (SMEs), a common profile for innovative biotech firms, any unused credit is immediately refundable, providing a vital source of non-dilutive funding.

Crucially, the CIR framework covers R&D work subcontracted to approved public or private research organizations. By securing this approval, Intravacc is now positioned within this exclusive ecosystem. For a French biotech, this means that partnering with the Dutch CDMO on complex tasks like vaccine strain design, process development, or cGMP clinical batch production becomes substantially more cost-effective, directly reducing their net R&D spend.

A Strategic Advantage in a Competitive Market

Intravacc's CIR approval is more than a procedural certification; it's a sharp competitive tool in the booming European CDMO market, a sector projected to swell to nearly $95 billion by 2035. In this crowded field, which includes industry giants like Lonza and Catalent, differentiation is key. While many CDMOs offer technical excellence, the ability to deliver it with a direct, government-backed financial benefit for the client is a powerful advantage.

This move places Intravacc among a select group of non-French CDMOs, including NorthX Biologics and 3P Biopharmaceuticals, that have successfully navigated the French ministry's approval process. This trend highlights a growing recognition that securing such certifications is a vital part of a European market penetration strategy, especially for attracting clients from France's robust life sciences hub.

By obtaining this status, Intravacc not only lowers the financial barrier for French partners but also signals its commitment to the French market and its understanding of the local innovation funding landscape. The company has stated it will support partners with precise project scoping and invoicing to ensure seamless alignment with CIR documentation requirements, further smoothing the path for collaboration.

A Catalyst for the French Biotech Ecosystem

The most immediate impact of this development will be felt within France's vibrant biotech sector. The approval effectively makes Intravacc's comprehensive suite of services—spanning viral, bacterial, and protein-based vaccine platforms—more accessible to a broader range of French companies, from early-stage startups to established pharmaceutical players.

For smaller firms, which often operate with lean budgets, the opportunity to outsource capital-intensive and technically demanding work to a specialist like Intravacc without bearing the full cost can be transformative. It allows them to advance their pipelines and reach critical clinical milestones faster, all while conserving capital for their core research activities.

In the press release, Intravacc’s managing director, Ivo Lemmens, emphasized this collaborative spirit. “I am pleased that Intravacc has received CIR approval for 2025-2027,” he stated. “This recognition supports our commitment to helping French and European partners accelerate vaccine innovation while reducing development risk. By combining our vaccine development know-how, advanced analytical capabilities and cGMP manufacturing expertise, we can support partners from early concept to clinical proof of concept.”

A Model for Public-Private Synergy in Health Security

Beyond the immediate business implications, Intravacc's CIR approval exemplifies a broader trend in global health: the increasing importance of synergy between government policy and specialized private sector expertise. In a post-pandemic world, the need for agile and resilient vaccine development and manufacturing infrastructure has never been clearer. Financial instruments like the CIR are not merely economic tools; they are strategic mechanisms to bolster national and regional health security.

By incentivizing French companies to partner with a highly specialized vaccine CDMO, the French government is indirectly fostering the development of its domestic innovation pipeline. This creates a win-win scenario: Intravacc strengthens its European market position and secures a new stream of high-value projects, while French biotechs gain a cost-effective path to world-class development and manufacturing capabilities.

This symbiotic relationship—where public incentives fuel private sector partnerships to achieve national scientific and health objectives—offers a powerful model for the future. As Intravacc begins to leverage its new status, the arrangement will serve as a key case study in how targeted financial policies can accelerate the translation of scientific discovery into tangible medical progress.